RSV-MEDI deltaM2-2 vaccine (NIAID/MedImmune/Johns Hopkins Bloomberg)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameRSV-MEDI deltaM2-2 vaccine (NIAID/MedImmune/Johns Hopkins Bloomberg)
Drug Alias NameRSV LID deltaM2-2 1030s vaccineRSV cps2 vaccine (NIAID)live attenuated vaccine (NIAID/MedImmune/Johns Hopkins Bloomberg)RSV LID deltaM2-2 vaccine (NIAID)RSV LID deltaM2-2 vaccine (NIAID/MedImmune/Johns Hopkins Bloomberg) +[7] 
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Live attenuated vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthJohns Hopkins Bloomberg School Of Public HealthMedimmune Llc +[4] 
Inactive CompaniesN/A
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A